Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Top Cited Papers
- 19 December 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 387 (10027), 1540-1550
- https://doi.org/10.1016/s0140-6736(15)01281-7
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatmentJournal of Translational Medicine, 2013
- 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?Scientific Reports, 2012
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- THE B7 FAMILY REVISITEDAnnual Review of Immunology, 2005
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000
- The Efficiency of Cox's Likelihood Function for Censored DataJournal of the American Statistical Association, 1977